Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC

Digestive and Liver Disease

Volumn 48, Issue 7, 2016, Pages 780-784

  Mazzaro, Cesare ^a   Dal Maso, Luigino ^a   Urraro, Teresa ^b   Mauro, Endri ^c   Castelnovo, Laura ^d   Casarin, Pietro ^c   Monti, Giuseppe ^d   Gattei, Valter ^a   Zignego, Anna Linda ^b   Pozzato, Gabriele ^e  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Pordenone General Hospital   (Italy)

^d Ospedale di Saronno   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Cryoglobulinemia; Entecavir; Hepatitis B virus; Vasculitis

Indexed keywords

ADEFOVIR; ALPHA2B INTERFERON; CORTICOSTEROID; ENTECAVIR; LAMIVUDINE; NUCLEOTIDE; RHEUMATOID FACTOR; ADENINE; ANTIVIRUS AGENT; GUANINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CRYOGLOBULINEMIA; CRYOGLOBULINEMIC VASCULITIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; GLOMERULONEPHRITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ITALY; KIDNEY FAILURE; LIVER CIRRHOSIS; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PURPURA; RARE DISEASE; TREATMENT RESPONSE; VASCULITIS; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; TREATMENT OUTCOME;

ADENINE; AGED; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; ITALY; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; TREATMENT OUTCOME; VASCULITIS;

EID: 84963805276     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.03.018     Document Type: Article

References (40)

1. Gamen D., Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. New England Journal of Medicine 2004, 350:1118-1129.
2. Wright T.L., Lau J.Y. Clinical aspects of hepatitis B virus infection. Lancet 1993, 342:1340-1344.
3. Cacoub P., Sadoun D., Bourliere M., et al. Hepatitis B virus genotypes and extrahepatic manifestations. Journal of Hepatology 2005, 43:764-770.
4. Cacoub P., Terrier B. Hepatitis B-related autoimmune manifestations. Rheumatic Disease Clinics of North America 2009, 35:125-137.
5. Filer A., Hughes A., Kane K., et al. Successful treatment of hepatitis B-associated vasculitis using lamivudine as the sole therapeutic agent. Rheumatology 2001, 40:1064-1065.
6. Stecevic J., Pevzner M., Gordon S. Successful treatment of hepatitis B-associated vasculitis with lamivudine. Journal of Clinical Gastroenterology 2003, 36:451.
7. Sawabe T., Uenotsuchi T., Imafuku S., et al. Remission of hepatitis B virus-related vasculitis with lamivudine. Annals of Internal Medicine 2004, 140:672-673.
8. Enomoto M., Makanishi T., Ishii M., et al. Entecavir to treat hepatitis B-associate cryoglobulinemic vasculitis. Annals of Internal Medicine 2008, 149:912-913.
9. Conca P., Riccio A., Tarantino G. Successful lamivudine monotherapy in an elderly patient suffering from HBV-related decompensated cirrhosis associated with widespread leukocytoclastic vasculitis. International Journal of Immunopathology and Pharmacology 2009, 22:531-535.
10. Boglione L., D'Avolio A., Cariti G., et al. Tellbivudine in treatment of hepatitis B-associated cryoglobulinemia. Journal of Clinical Virology 2013, 56:167-169.
11. Vigano M., Martin P., Cappelletti M., et al. HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with Entecavir. Kidney and Blood Pressure Research 2014, 39:65-73.
12. Brouet J.C., Cauvel J.P., Danon F., et al. Biologic and clinical significance of cryo globulins. A report of 86 cases. American Journal of Medicine 1974, 57:775-788.
13. Gorevicc P.D., Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: implication for the relationship of MC to rheumatic and lymphoproliferative diseases. Seminars in Hematology 1991, 28:79-94.
14. Ferri C., Zignego A.L., Giuggioli D., et al. HCV and cryoglobulinemic vasculitis. Cleveland Clinic Journal of Medicine 2002, 69(Suppl. 2):SII20-SII23.
15. Cacoub P., Gragnani L., Comarmond C., et al. Extrahepatic manifestations associated with hepatitis C virus infection. Digestive and Liver Disease 2014, 46:S165-S173.
16. Johnson R.J., Grecht D.R., Yamabe H., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. New England Journal of Medicine 1993, 328:465-470.
17. Yamabe H., Johnson R.J., Grecht D.R., et al. Hepatitis C virus infection and membrano-proliferative glomerulonephritis in Japan. Journal of the American Society of Nephrology 1995, 6:220-223.
18. Fabrizi F., Lunghi G., Messa P., et al. Therapy of hepatitis C virus associated glomerulonephritis: current approaches. Journal of Nephrology 2008, 21:813-825.
19. Perico N., Cattaneo D., Bikbov B., et al. Hepatitis C infection and chronic renal disease. Clinical Journal of the American Society of Nephrology 2009, 4:207-208.
20. Mazzaro C., Monti G., Saccardo F., et al. Efficacy and safety of peginterferon alpha-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clinical and Experimental Rheumatology 2011, 29:933-941.
21. Pietrogrande M., De Vita S., Zignego A.L., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected 215 patients. Autoimmunity Reviews 2011, 10:444-454.
22. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximabin type II mixed cryoglobulinemia. Blood 2003, 15:101-110.
23. Sansonno D., De Re V., Lauletta G., et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003, 101:3818-3826.
24. Hagan M., Asrani S.K., Talwalkar J. Non-invasive assessment of liver fibrosis and prognosis. Expert Review of Gastroenterology & Hepatology 2015, 9:1251-1260.
25. Mazzaro C., Zorat F., Comar C., et al. Interferon-alpha plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. Journal of Rheumatology 2003, 30:1775-1781.
26. Cakir N., Nuri Pamuk O., Umit H., et al. Successful treatment with Adefovir of one patient whose cryoglobulinemic vasculitis relapsed under Lamivudine therapy and who was diagnosed to have HBV virologic breakthrough with YMDD mutations. Internal Medicine 2006, 45:1213-1215.
27. Tarantino A., Campise M., Banfi C., et al. Long term predictors of survival in 209 essential mixed cryoglobulinemic glomerulonephritis. Kidney International 1995, 47:618-623.
28. Mazzaro C., Panarello G., Tesio F., et al. Hepatitis C virus risk: a hepatitis C virus related syndrome. Journal of Internal Medicine 2000, 247:535-545.
29. Elewa U., Sandri A., Kim R., et al. Treatment of hepatitis B virus-associated nephropaty. Nephron Clinical Practice 2011, 119:c41-c49.
30. Yang Y., Xiong Q., Zhao W., et al. Complete remission of hepatitis B virus related membranous nephropaty after Entecavir monotherapy. Clinics and Research in Hepatology and Gastroenterology 2012, 36:e89-e92.
31. Quartuccio L., Soardo G., Romano G., et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006, 45:842-846.
32. Roccatello D., Baldovino S., Rossi D., et al. Long-term effects of anti-CD20244 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrology, Dialysis, Transplantation 2004, 19:3054-3061.
33. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology 2012, 57:167-185. Epub 2012 March 20: No abstract available. Erratum in: Journal of Hepatology 2013;58:201. Janssen, Harry [corrected to Janssen, Harry LA].
34. Tassopoulos N.C., Volpes R., Pastore G., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999, 29:889-896.
35. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New England Journal of Medicine 2003, 348:800-807. Erratum in: New England Journal of Medicine 2003;348:1192.
36. Marcellin P., Bonino F., Lau G.K., et al. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009, 136:2169-2179.
37. Marcellin P., Piratvisuth T., Brunetto M., et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2A ± lamivudine: results of 5-year post-treatment follow up. Journal of Hepatology 2009, 50(Suppl. 1):S336.
38. Marcellin P., Buti M., Gane E.J., et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011, 54(Suppl. 1):1011A.
39. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-1751.
40. D'Amico E., Pace-Palitti V., Di Lembo E., et al. Successful treatment of hepatitis B virus infection and related cryoglobulinemic purpura with nucleotide analogues. Clinical and Experimental Rheumatology 2013, 31:1559.